glp-1 ckd Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists Recommendations for SGLT2i versus GLP-1

Some patients may experience persistent mild bloating that becomes their "new normal" on therapy

It alerts healthcare professionals (HCPs) to the potential risk of pulmonary aspiration in people using GLP-1 or dual GIP/GLP-1 receptor agonists (RAs) who undergo surgery or procedures with general anaesthesia or deep sedation

This structural modification strategy has been pivotal in the development of GLP-1 receptor agonists with extended plasma half-lives [17]

Protect from light and avoid temperature fluctuations

Compare the two in our retatrutide vs

Bethel et al included the trials LEADER, SUSTAIN 6, EXSCEL, HARMONY, REWIND, and PIONEER-6 in their meta-analysis and found that GLP-1RAs were associated with DR